Citations

Clear

9 citation(s) found for "Halter, Jörg".

A discrete event simulation to evaluate impact of radiology process changes on emergency department computed tomography access
Maass, Kayse Lee , Halter, Elizabeth, Huschka, Todd R., Sır, Mustafa Y. , Nordland, Michelle R., Pasupathy, Kalyan S.

Mayo Clinic

Journal of Evaluation in Clinical Practice | July 26, 2021 | Volume: 28 | Issue: 1 | Pages: 120-128

10.1111/jep.13606 | PMID 34309137 Get It

AbstractBackgroundHospitals face the challenge of managing demand for limited computed tomography (CT) resources from multiple patient types while ensuring timely access.MethodsA discrete event simulation model was created to evaluate CT access time for emergency department (ED) patients at a large academic medical center with six unique CT machines that serve unscheduled emergency, semi‐scheduled inpatient, and scheduled outpatient demand. Three operational interventions were tested: adding additional patient transporters, using an alternative creatinine lab, and adding a registered nurse dedicated to monitoring CT patients in the ED.ResultsAll interventions improved access times. Adding one or two transporters improved ED access times by up to 9.8 minutes (Mann‐Whitney (MW) CI: [−11.0,−8.7]) and 10.3 minutes (MW CI [−11.5, −9.2]). The alternative creatinine and RN interventions provided 3‐minute (MW CI: [−4.0, −2.0]) and 8.5‐minute (MW CI: [−9.7, −8.3]) improvements.ConclusionsAdding one transporter provided the greatest combination of reduced delay and ability to implement. The projected simulation improvements have been realized in practice.
Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study
Armand, Philippe , Pérez, Waleska S., Zhang, Mei‐Jie , Kim, Haesook , Klumpp, Thomas R., Cin, Paola Dal , Litzow, Mark R. , Cahn, Jean‐Yves , Schouten, Harry C. , Ball, Edward D., Aljurf, Mahmoud , Rowe, Jacob M. , Antin, Joseph H. , Isola, Luis , Bartolomeo, Paolo Di , Camitta, Bruce M., Miller, Alan M. , Cairo, Mitchell S. , Savoie, Mary Lynn , Halter, Joerg , Stiff, Patrick J. , Nabhan, Chadi , Jakubowski, Ann A. , Bunjes, Donald , Petersdorf, Effie W. , Lewis, Victor , Marks, David I. , Bredeson, Christopher , Soiffer, Robert J. , Waller, Edmund K. , Liesveld, Jane L. , Lazarus, Hillard M. , Artz, Andrew , Gupta, Vikas , Savani, Bipin N. , McCarthy, Philip L. , Finke, Jürgen , Cutler, Corey S. , Stockerl‐Goldstein, Keith , Sierra, Jorge , Halter, Jörg , Devine, Steven M. , Maziarz, Richard Thomas , Bornhäuser, Martin , Weisdorf, Daniel J.

Mayo Clinic

Blood | October 13, 2019 | Volume: 116 | Issue: 21 | Pages: 680-680

10.1182/blood.v116.21.680.680 Get It

Abstract Abstract 680 Cytogenetics play an essential role in determining the prognosis of patients with AML. However, there is still no validated cytogenetics grouping scheme that specifically applies to patients undergoing allogeneic stem cell transplantation, which hampers accurate prognostication and risk stratification. We studied 821 adult patients (median age 41, range 18–74) who underwent SCT between 1999 and 2004 for AML (excluding APL) in CR1 or CR2 and who were reported to the CIBMTR from centers with >20 patients meeting study criteria. 75% of patients received a myeloablative conditioning. 496 patients had a normal karyotype. The primary cytogenetics reports were manually reviewed for 92% of the patients with an abnormal karyotype. We compared the ability of the 6 existing grouping schemes (MRC, CALGB, EORTC/GIMEMA, SWOG/ECOG, DFCI, and Monosomal Karyotype (MK) classifications) to stratify patients, using both the Akaike Information Criterion in multivariable models and the C-statistic. Among all existing schemes, the DFCI system provided a marginally superior stratification for overall and leukemia-free survival. We also built a new classification using individual cytogenetic abnormalities in a Cox model that included other significant covariates (performance status, therapy-related disease, conditioning intensity, graft source, donor match, duration of CR1, and gender match). This CIBMTR scheme (see Table), which is similar to the DFCI scheme except for the inclusion of patients with t(8;21) in the intermediate group, could stratify patients into 3 groups with similar treatment-related mortality but significantly different overall survival, leukemia-free survival, and incidence of relapse. This scheme appeared to apply to both patients in CR1 and in CR2 (see FiguresF2). This transplant-specific scheme could be adopted for prognostication purposes and to stratify patients with karyotypic abnormalities entering transplantation clinical trials. Future studies may clarify the relative outcome of patients with t(8;21) and refine this scheme with the inclusion of molecular abnormalities. Disclosures: No relevant conflicts of interest to declare.
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, Derek, Biessels, Geert Jan , Braithwaite, Susan S., Draznin, Boris , Halter, Jeffrey B., McDonnell, Marie E. , Molitch, Mark E. , Murad, M. Hassan , Murad, M Hassan , McDonnell, Marie E , Biessels, Geert Jan , Casanueva, Felipe F. , Hirsch, Irl B. , Sinclair, Alan J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1520-1574

10.1210/jc.2019-00198 | PMID 30903688 Get It

Abstract Objective The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.
Disease drivers of aging
Hodes, Richard J. , Sierra, Felipe , Austad, Steven N. , Epel, Elissa S. , Schafer, Marissa , LeBrasseur, Nathan K. , Wiley, Christopher D. , Campisi, Judith , Sehl, Mary E. , Scalia, Rosario , Eguchi, Satoru , Kasinath, Balakuntalam S. , Halter, Jeffrey B., Cohen, Harvey Jay, Demark‐Wahnefried, Wendy , Ahles, Tim A. , Barzilai, Nir , Hurria, Arti , Hunt, Peter W. , Schafer, Marissa J, Neigh, Gretchen N. , Erlandson, Kristine M. , LeBrasseur, Nathan K , Schafer, Marissa J , Demark-Wahnefried, Wendy

Mayo Clinic

Annals of the New York Academy of Sciences | December 14, 2016 | Volume: 1386 | Issue: 1 | Pages: 45-68

10.1111/nyas.13299 | PMID 27943360 Get It

It has long been known that aging, at both the cellular and organismal levels, contributes to the development and progression of the pathology of many chronic diseases. However, much less research has examined the inverse relationship—the contribution of chronic diseases and their treatments to the progression of aging‐related phenotypes. Here, we discuss the impact of three chronic diseases (cancer, HIV/AIDS, and diabetes) and their treatments on aging, putative mechanisms by which these effects are mediated, and the open questions and future research directions required to understand the relationships between these diseases and aging.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Ringdén, Olle , Pavletic, Steven Z. , Anasetti, Claudio , Wang, Tao , Antin, Joseph H. , Bartolomeo, Paolo Di , Bolwell, Brian J., Bredeson, Christopher , Cairo, Mitchell S. , Gupta, Vikas , Hahn, Theresa , Hale, Gregory A., Halter, Jörg , Jagasia, Madan , Litzow, Mark R. , Marks, David I. , Cowan, Morton J. , Petersdorf, Effie W. , Russell, James A. , Schiller, Gary J. , Schouten, Harry C. , Verdonck, Leo F. , Horowitz, Mary M. , Arora, Mukta , Barrett, A. John , Wang, Dan , Gale, Robert Peter , Locatelli, Franco , McCarthy, Philip L. , Spellman, Stephen R. , Wingard, John R. , Halter, Joerg , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Blood | December 5, 2008 | Volume: 113 | Issue: 13 | Pages: 3110-3118

10.1182/blood-2008-07-163212 | PMID 19059878 Get It

AbstractDo some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]–matched, n = 941) or HLA-identical sibling donor (n = 3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P < .001) and relapse (RR, 1.50; P < .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P < .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
Hahn, Theresa , Zhang, Mei-Jie , Wang, Dan , Arora, Mukta , Frangoul, Haydar , Hale, Gregory A., Horan, John , Isola, Luis , Rood, Jon J. van, Gupta, Vikas , Halter, Joerg , Reddy, Vijay , Tiberghien, Pierre , Litzow, Mark R. , Anasetti, Claudio , Pavletic, Stephen, Ringdén, Olle , Halter, Jörg , McCarthy, Philip L. , Gale, Robert Peter , Maziarz, Richard Thomas , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Journal of Clinical Oncology | November 4, 2008 | Volume: 26 | Issue: 35 | Pages: 5728-5734

10.1200/jco.2008.17.6545 | PMID 18981462 Get It

Purpose Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved. Patients and Methods Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk. Results Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL. Conclusion This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.